Cart
sales@molnova.com
Tyroserleutide TFA
CAS No. ———
Tyroserleutide TFA( ——— )
Catalog No. M40612 CAS No. ———
Tyroserleutide TFA, isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTyroserleutide TFA
-
NoteResearch use only, not for human use.
-
Brief DescriptionTyroserleutide TFA, isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.
-
DescriptionTyroserleutide TFA, isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number———
-
Formula Weight———
-
Molecular Formula———
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Acetyl-δ-Endorphin (...
Acetyl-δ-Endorphin (bovine, camel, mouse, ovine)
-
LY195448
LY 195448 (4-(3-(2-Hydroxy-2-phenyl)ethylamino-3-methylbutyl)benzamide) is a substance present in human blood and urine that shows antitumor activity in a mouse tumor model and blocks cells in the mid-stage.
-
ZINC77292789
Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a reagent for the preparation of a synthetic MUC1 Glycopeptide Bearing βGalNAc-?Thr as a Tn antigen isomer which induces the antibody production against tumor cells. Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a starting material to make trimeric MUC1 immunodominant motif antigen-?based anti-?cancer vaccine candidates.
